|[December 17, 2013]
Stelis Biopharma and Pieris Forge Alliance for Novel Anticalin® Therapeutics in Ophthalmology
BANGALORE, India & FREISING, Germany --(Business Wire)--
Stelis Biopharma (formerly Agila Biotech), a subsidiary of Strides
Arcolab Limited, focused on biotherapeutic drug development
and bio-manufacturing, and Pieris AG, a next generation therapeutic
protein R&D company, announced the initiation of a long-term
collaboration for clinical development and commercialization of multiple
novel Anticalin®-based protein therapeutics worldwide,
primarily focusing on ophthalmology. The alliance deploys the synergies
of Pieris' innovative drug discovery and early development capabilities
with Stelis' strong bio-manufacturing and clinical development
expertise. Under the terms of the agreement, Pieris will advance each
collaborative program through in vivo proof of concept, at which stage
Stelis will be responsible for drug manufacturing and advancing the
molecule through a first-in-human clinical study. Following positive
clinical data, the parties will co-develop programs under a joint
Dr. Anand Iyer, CEO of Stelis commented, "Our alliance with Pieris
demonstrates how Stelis' strategic investments into state-of-the-art
manufacturing facilities are attracting partners with cutting edge
biologics such as Anticalins, which hold great promise in the ophthalmic
space." Pieris CEO, Stephen Yoder, stated, "Today's announcement is
another example of how Pieris is finding innovative structures and
committed partners to advance several Anticalins to the clinic in areas
of high unmet need. Our strategic relationship with Stelis provides
access to bio-manufacturing capabilities of the highest standard, yet in
a very cost-effective manner."
About Stelis Biopharma / Strides Arcolab Ltd.
Stelis Biopharma Private Limited, India (formerly known as Agila
Biotech Private Limited, India), is a wholly owned subsidiary of Strides
Arcolab Limited, India. Stelis Biopharma (Malaysia) Sdn Bhd
(formerly known as Agila Biotech (Malaysia) Sdn Bhd), is a wholly owned
subsidiary of Stelis Biopharma Private Limited, India.
Stelis Biopharma is building a state-of-the-art R&D in Bangalore
(India) to research, and develop biotherapeutic drugs and devices
including, but not limited to, biosimilars, biobetters, NBEs, novel
formulations and drug loaded devices. The Company is also building a
state-of-the-art, fully integrated manufacturing facility at Bio-Xcell's
biotechnology park in Nusajaya, within the Iskandar region of Johor,
Malaysia for the manufacture of biotherapeutics and devices.
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531)
and National Stock Exchange of India Limited (STAR (News - Alert)), is a global
pharmaceutical Company headquartered in Bangalore, India that develops
and manufactures a wide range of IP-led niche pharmaceutical products.
The Company has 5 manufacturing facilities presence in more than 75
countries in developed and emerging markets.
Additional information is available at the Company's website at www.stridesarco.com.
About Pieris & Anticalins
Pieris AG is an independent, clinical-staged biotechnology company
advancing its proprietary Anticalin® technology to create
differentiated drugs that are safer and more effective than conventional
approaches. Exclusive to Pieris, Anticalins promise to address
high-unmet medical needs and expand the potential of targeted
therapeutics. The company currently has a diverse proprietary pipeline
and has, in addition to Stelis, ongoing R&D collaborations with Daiichi
Sankyo, the Sanofi Group, Zydus Cadila and Allergan. Privately held,
Pieris has been funded by premier biotechnology-focused venture capital,
including lead investors OrbiMed Advisors and Global Life Science
Anticalins® are recombinantly engineered versions of human lipocalins,
low-molecular weight polypeptides that naturally bind, store and
transport a wide spectrum of molecules. To make Anticalins, Pieris makes
discrete changes to those lipocalin amino acid positions responsible in
endogenous ligand binding, thereby redirecting specificity away from the
natural ligand and to virtually any target of interest. By utilizing an
endogenous binding protein as a template, Pieris "hijacks" the natural
function of the lipocalin to enable diverse therapeutic applications.
Anticalin®, Anticalins® are registered trademarks
of Pieris AG.
[ Back To Technology News's Homepage ]